רווח למניה בשנים עשר החודשים האחרונים: Citius Oncology Inc. (CTOR)

The GURU.Markets base chart, which tracks the rolling annual EPS, illustrates the profit dynamics of Citius Oncology, Inc. (CTOR). The -0.47 level reflects the current value of this metric. Citius Oncology, Inc. (CTOR) is implementing AI automation to accelerate drug development. Future revenues are based on the commercialization of T-cell lymphoma therapies. Following the IPO, the strategy relies on expanding sales across US oncology clinics.

Given Citius Oncology, Inc. (CTOR) critical dependence on the commercial success of a single oncology drug, the issuer's financial stability correlates directly with the effective implementation of this asset. The 12-month EPS trend calculates a rolling net profit adjusted for share volume, allowing investors to objectively assess the real earnings per share and avoid overpaying for the asset.